MetaCap

Intellia Therapeutics (NTLA) vs Achieve Life Sciences (QUIT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Intellia Therapeutics is the larger company by market cap ($1.40 billion vs $573.2 million), about 2.4 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NTLA-17.29%QUIT-25.87%
+16%-6%-28%
Aug 17, 20261 yearNov 20, 2026
NTLA-22.12%QUIT-30.41%
+8%-12%-32%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NTLA versus QUIT key metrics
MetricNTLAQUIT
Share price$10.00$5.56
Market cap$1.40B$573.25M
1-day change+5.04%-5.28%
YTD return+11.23%—
1-year return+21.80%—
5-year return-91.16%—
EPS (TTM)$-3.35$-1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$67.67M—
Revenue growth (YoY)+16.92%—
Net income (latest FY)$-412.69M$-54.65M
Operating margin-651.67%—
Net margin-609.85%—
52-week high$18.48$8.64
52-week low$8.09$2.62
Distance from 52-week high-45.89%-35.65%
Analyst consensusbuystrong_buy
Avg. price target upside+127.80%+162.23%
Average volume5.03M1.38M
Shares outstanding140.36M103.10M
Employees37728
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Intellia Therapeutics is about 2.4 times larger than Achieve Life Sciences by market value ($1.40B vs $573.25M).

About Intellia Therapeutics

NTLA stock →

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees

About Achieve Life Sciences

QUIT stock →

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees

NTLA vs QUIT FAQ

Which is bigger, Intellia Therapeutics or Achieve Life Sciences?

Intellia Therapeutics (NTLA) is larger, with a market capitalization of $1.40B compared with $573.25M for Achieve Life Sciences (QUIT).

Are Intellia Therapeutics and Achieve Life Sciences in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons